Objective To prepare a target phase variant cationic lipid nanoparticle (INP), which is encapsulated with ICG, to connect the CD105 antibody, to detect its photothermal effect, in vitro phase transition, photoacoustic and ultrasonic imaging, and to confirm the successful connection of the nanoparticle antibody. Methods The cationic lipid nanoparticles with ICG and liquid fluorine carbon (PFP) were prepared by double emulsification method, the linkage of CD105 antibody by streptomyces affinity, flow cell quantification and laser confocal observation of antibody connection; The photothermal effect and phase transition were observed after laser irradiation. After the phase change through Lifu irradiation in vitro, the ultrasound imaging was recorded. The photoacoustic imaging capability is detected by a photoacoustic instrument. Results The average particle size (354.2±93.85nm), average potential (25.2±3.29mv) and CD105 antibody binding rate were 99.89, the nanoparticles had good photothermal effect, and the 180s temperature of 2w/cm2 laser irradiation could rise to 63 ℃ at a certain concentration, the INP Liquid gas phase change can occur. In vitro ultrasound and photoacoustic imaging effect is good. Conclusion The target phase variant cationic lipid nanoparticles (INP) coated with ICG were successfully prepared, and the effect of light thermal effect, photoacoustic imaging and enhanced ultrasound was good, and the binding rate of nanoparticles and CD105 antibody was high.